title: Effects of mibefradil on uterine contractility.
abstract: Mibefradil, a benzimidazolyl tetralol derivative, is a new Ca(2+) channel antagonist which is structurally distinct from other Ca(2+) channel antagonists such as nifedipine, verapamil and diltiazem. It is a very effective antihypertensive agent that is thought to achieve its action via a higher affinity block for low-voltage activated (T) than for high-voltage-activated (L) Ca(2+) channels. Nevertheless, it blocks L-type Ca(2+) channels in several tissues. In the present study, the effects of mibefradil on spontaneous rhythmic contractions and on contractions elicited by CaCl(2) (K(+)-depolarized preparations) and oxytocin (in low Ca(2+)/Ca(2+)-free solutions) were investigated on uterus strips from pregnant and non-pregnant rats. Mibefradil (10(-8)-3 x 10(-6) M) caused concentration-dependent inhibition of spontaneous contractions of uterus strips from pregnant and non-pregnant rats with the IC(50) values of 8.83 x 10(-7) M; 5.94 x 10(-7) M (amplitude) and 1.03 x 10(-6) M; 5.48 x 10(-7) M (frequency), respectively. Mibefradil (3 microM) caused a rightward shift in the concentration-response curves for CaCl(2) in K(+) (40 mM)-depolarized uterus strips taken from both pregnant and non-pregnant rats. Mibefradil (3 microM) was, however, more potent for antagonising CaCl(2) responses in uterus strips obtained from pregnant rats than in those from non-pregnant rats. Mibefradil (3 microM) had no effect on oxytocin-induced contraction in Ca(2+)-free physiological salt solution (PSS) on uterus strips from non-pregnant rats. However, it markedly inhibited oxytocin-induced contraction of pregnant rat uterus strips in Ca(2+)-free PSS. Thus, mibefradil probably antagonizes L-type Ca(2+) channels as well as interferes with the intracellular Ca(2+) release mechanism, which would be helpful in the development of a tocolytic agent.
authors.affiliation: Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, 243 122 Uttar Pradesh, India.
authors.forename: Keerai T
authors.initials: KT
authors.lastname: Asokan
authors.forename: Souvendra N
authors.initials: SN
authors.lastname: Sarkar
authors.forename: Santosh K
authors.initials: SK
authors.lastname: Mishra
authors.forename: Vellanki
authors.initials: V
authors.lastname: Raviprakash
mesh_terms: D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002122:Calcium Chloride / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D020748:Mibefradil / Q000494:pharmacology*; D009543:Nifedipine / Q000494:pharmacology; D010121:Oxytocin / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D002121:Calcium Channel Blockers; D020748:Mibefradil; D010121:Oxytocin; D009543:Nifedipine; D002122:Calcium Chloride